Featured · US Pharma
FDA Loosening, an M&A Wave, GLP-1s Into Medicare: The Three-Gate Repricing of US Pharma
Through three lenses — regulatory approvals, M&A premiums, and payer coverage — we ask whether pharma's valuation anchor is shifting, and map out which kinds of companies could get repriced.
Read the research →
Latest Research
Research Articles
Read it like a research blog: start with the featured piece, then browse the article list.
The triple-gate repricing of U.S. pharma
When regulation, dealmaking, and payer coverage shift at the same time, pharma's valuation debate tends to move from single catalysts to a systemic repricing.
Read the research →
The memory supercycle: full-chain repricing across A-shares, Hong Kong, and U.S. markets
Korea's largest-ever semiconductor investment, end-market price hikes, and the HBM upgrade cycle are converging — pushing memory from a bottom-of-cycle beta trade into a capacity-driven upleg.
Read the research →
Hong Kong Liquidity and China Internet
Tracking southbound flows, dollar liquidity, earnings recovery, and risk appetite to judge whether the China internet rally can graduate from valuation repair to fundamental proof.
Read the research →
Gold, the dollar, and real rates
Breaking the gold trade into four threads — real rates, the dollar, safe-haven demand, and central bank buying — to separate trend allocation from short-term trading signals.
Read the research →
The key variables in the Nvidia thesis
Continuously recalibrating NVDA's growth slope and valuation ceiling against cloud capex, order momentum, gross margins, and inference demand.
Read the research →
AI investing tools compared
Comparing general-purpose chat tools with a purpose-built research agent workflow — and how NashNova compounds tracking frameworks and risk variables over time.
Read the research →